Drug
Nisevokitug clinical trials
Also written NIS793.
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 2
Novartis Pharmaceuticals (5) · Colin D. Weekes, M.D., PhD (1) · Kimberly Perez, MD (1)
Often tested with
Tested in the same studies.
Spartalizumab (2) · Sabatolimab (2) · Canakinumab (1) · Decitabine (1)
Studies
Open first, then newest update. How each study uses nisevokitug is read from its arms, and is right about nine times in ten.
Testing it · 7
- Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2CompletedPhase 3Novartis PharmaceuticalsNCT04935359Written as NIS793
- FOLFIRINOX + NIS793 in Pancreatic CancerTerminatedPhase 1Colin D. Weekes, M.D., PhDNCT05417386Written as NIS793
- Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)TerminatedPhase 2Novartis PharmaceuticalsNCT04390763Written as NIS793
- Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDSTerminatedPhase 1Novartis PharmaceuticalsNCT04810611Written as NIS793
- Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRCTerminatedPhase 2Novartis PharmaceuticalsNCT04952753Written as NIS793
- A Trial of NIS793 With FOLFIRINOX in Pancreatic CancerTerminatedPhase 2Kimberly Perez, MDNCT05546411Written as NIS793
- Study of Select Combinations in Adults With MyelofibrosisWithdrawnPhase 1Novartis PharmaceuticalsNCT04283526Written as NIS793
Given in every arm · 2 — nisevokitug is usual care beside what is tested
- Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis PatientsTerminatedPhase 1/2Novartis PharmaceuticalsNCT04097821Written as NIS793
- Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.CompletedPhase 1Novartis PharmaceuticalsNCT02947165Written as NIS793
Codes
What other systems call nisevokitug · ClinicalTrials.gg INT018297
- UNII (FDA) W2OR26S7UENISEVOKITUGOne source FDA
- NCI Thesaurus C132250NisevokitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W2OR26S7UE | NISEVOKITUG | One source FDA |
| NCI Thesaurus | C132250 | Nisevokitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.